Yaru Xu

The paper identifies RUNX1T1 as a marker of lineage plasticity across cancers and shows that targeting the RUNX1T1-HDAC complex can suppress plastic cell growth.

This study identifies TET2 activation in slow-cycling cells as a driver of prostate cancer progression through epigenetic changes and shows targeting TET2 suppresses tumor growth.

This study shows ZNF397 loss leads to TET2-driven epigenetic changes, lineage plasticity, and resistance to AR-targeted therapies in AR-dependent cancers, with TET2 inhibitors reversing resistance.